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Introduction: 
 
Finding the cure for cancer is a major area of focus in today’s medicinal world. Statistics 
stated in 2013 that 1 in 4 deaths in the United States can be attributed to cancer.1 The matter of 
curing cancer is highly complex. Practically, it is difficult to create a compound that will kill 
diseased tissues without affecting healthy tissues.2 In general cancerous cells are analogous                                
to healthy tissues; they simply have upregulated metabolic function leading to uncontrolled 
growth. This does lead to differences that can be targeted but finding these differences and 
creating therapeutics for these purposes requires a great deal of research. When researching new 
drugs, it is important to create experiments that emulate biological conditions. Tumors are not 
easy to replicate in a lab setting.3 This leads researchers to not only test viability of new drugs on 
diseased cells, but also to critically analyze the methods by which testing occurs. It is important 
to utilize in vitro method that bridges the gap between the lab and the clinical setting. 
One drug that has been developed and used affectively for the treatment of cancer is 
Cisplatin. This medication is a platinum-based compound that readily accepts the unpaired 
electrons of sulfur and nitrogen containing compounds to form dative bonds. This allows the 
platinum to bind with amino acids cysteine and methionine as well as many of the nitrogen bases 
of nucleotides deforming nuclear DNA.4 The damaging of the DNA initiates apoptosis.5 
Apoptosis is the desired method by which cancerous tissue is removed, because it is a controlled 
method of cell death that causes little inflammation. Alternately, necrosis, a method of cell death 
leading to inflammation and the damage of adjacent cells, is undesirable.6,7 Cisplatin is injected 
systematically into a patient’s circulatory system, and has been in use since FDA approval in 
1978.8 It has been considered an “essential medicine” by the World Health Organization.8  
The mechanism by which Cisplatin affects DNA begins when the two chlorine ligands 
are hydrolyzed, replaced by water molecules that donate a lone pair from the oxygen to the metal 
center. Plasma has a high water-content so it is possible that hydrolysis will occur prior to 
reaching diseased tissue. While this is the case, the chloride ion concentration is high in the 
blood when compared to the inside of a cell (100µM versus between 4 and 12µM). This 
difference allows the Cisplatin to maintain its integrity well enough in the blood to reach and act 
within cells.5 With this in mind, researchers often seek to create drugs with analogous 
mechanisms to Cisplatin’s. 
 Although Cisplatin has been highly beneficial for treating a wide range of cancers, it has 
drawbacks that require discussion. A report by Hazlitt et. al indicates that this drug causes an 
incidence of hearing loss for 63% of patients. The extent of hearing loss varies between 
individuals. Cisplatin reacts within auditory cells causing apoptosis and the generation of 
reactive oxygen species (ROS), a decrease in antioxidant enzymes, and an increase in 
proinflammatory cytokines.8 Resistance within center cancer types is another issue that 
diminishes the efficacy of Cisplatin’s use. Lung carcinoma tumor A549/CDDP is an example of 
a known resistant cell type.2 Currently, research is seeking the mechanism by which resistance 
occurs, but none of the accessed literature indicated a causative conclusion. To this point only 
hypotheses have been proposed. Researchers are currently unable to monitor all the reactions that 
Cisplatin undergoes within the cell due to miniscule concentrations. One theory is that tumors 
cells release excess amounts of glutathione (GSH).  Cisplatin theoretically binds to the sulfur in 
GSH prior to the being able reacting with DNA.4 The main reason for the side effects generally 
associated with chemotherapy is Cisplatin’s inability to affect diseased tissue without damaging 
healthy tissues. These include nausea and vomiting, loss of appetite, and hair loss. Since the 
regular cells grow back and tumor cells do not, the side effects are tolerated.7 
 
Ruthenium Complexes: Targeting DNA 
 
Current research is investigating ways to use ruthenium complexes as a substitute for 
Cisplatin in hopes of finding medicines that are more specific to cancerous cells and that reduce 
the side effects of chemotherapy. Due to the success of Cisplatin, many of these new drugs seek 
to target the DNA of diseased tissues. Cisplatin has a square planar geometry5 while ruthenium 
complexes have an octahedral geometry. This helps to increase the variability in the ligands 
attached to the metal center allowing for higher specificity in targeting diseased tissues.9 Many 
ruthenium complexes are used in medicine currently,7 but the ruthenium complexes specified for 
anticancer therapy have yet to become staples in treatment. It is desirable that some of them will 
be applied to regular use in the near future. In this summary, the attractive aspects of ruthenium 
complexes and the methods by which their efficacy is tested are investigated. 
Within the precious metal therapeutics, ruthenium is the only metal that forms stable 
complexes in oxidation states 2+ through 4+ under biological conditions. Ru(III) complexes are 
less biologically active when compared to Ru(II) and Ru(IV) compounds.7 Ruthenium is also in 
the same d-block triad as iron and are able to bind to the protein transferrin that is found in a 
higher amount on the outside of tumor cells as opposed to healthy cells. This diminishes the 
chances of uptake of Ru complexes into healthy cells. Transferrin binds to the complex and 
actively transports it into the cell.10 Once there, the molecules are in an environment with low 
oxygen levels. The hypoxic environment of diseased tissue leads to the reduction of Ru(III) to 
Ru(II), the more reactive species.6,11 Even if some of the Ru(III) compound were to be moved 
into a healthy cell, the higher amount of oxygen would decrease the likelihood that reduction 
would occur. As the reduced form, the complex theoretically will damage cancerous cell DNA 
by causing cross-links that lead to apoptosis. One theory of the incidence of cross-linking is that 
the octahedral geometry of ruthenium drugs leads to a “steric restriction.” This proposed 
mechanism differs from the mechanism that Cisplatin employs to cause DNA deformation. 
Research believe this may be why the drugs with Ru overcome the resistance some tumors show 
towards the platinum drug.7 
Another aspect of ruthenium complexes that makes them of interest is their similarity to 
platinum’s ligand exchange.7 Ligand exchange determines biological activity of a complex. 
Metal complexes are often activated when the ligands attached to the metal center react with 
compounds with which they come in contact. If the ligands do not remain bound to the metal 
center until they reach the desired location, the anticipated outcome will not result.7,9 In the case 
of anti-cancer agents, this result is stopping metastasis and/or causing cell death of diseased 
tissue. Ruthenium complexes have shown to bind to DNA just as platinum based drugs do, but 
many lack solubility which makes it difficult for them to be transported through the circulatory 
system.6,7 Using the dialkyl sulfoxide derivative dimethylsulfoxide (DMSO) researchers were 
able to create a soluble compound called NAMI-A. This compound binds to DNA much weaker 
than Cisplatin12, and in vivo trials did not indicate DNA damage as the anticancer mechanism.7 
This was considered the most promising Ru(II) complex in 20017 due to the antimetastatic 
capabilities.12 These antimetastatic capabilities are the reason it is called NAMI which means 
“new anticancer metastasis inhibitor.”  
Researchers have a litany of ligands to choose from that affect the characteristics of the 
complex. Since anticancer agents are injected through into the blood stream, researchers must 
create drugs that are able to dissolve in the blood without reacting. Patra, et. al describe a method 
of incubation in human plasma that is utilized to test whether or not a substance degrade in an 
environment that simulates blood flow.13 The substance in question is added along with an 
equivalent volume of diazepam solution to blood plasma obtained commercially. This solution is 
incubated with a gentle stirring of 300 rpm at 37℃ for a period 24 hours or more. The 
researchers use this length of time because it far overshoots the time should remain in the blood 
prior to reaching its desired location. After incubation Patra, et. al used a 2:1 ratio by volume of 
methyl-tert-butyl ether/dichloromethane solution to stop any reaction that may be occurring. The 
solvent was allowed to evaporate, and the solution was centrifuged so the organic layer could be 
analyzed in HPLC-MS. A reverse phase column was used for the separation and ESI mode was 
used for the mass spectrometry analysis.13 Huang et. al used the same overall method as Patra et. 
al only making slight modifications they saw necessary for the testing of their proposed 
ruthenium anti-cancer therapeutics.2 Neither group explains explicitly how the decomposition of 
their respective target substances are compared. They only stated that each maintain integrity 
when incubated under the conditions previously described. It seems reasonable to assume that 
the substance and diazepam solution is simply tested through the same analytical methods, 
HPLC-MS, without incubation and compared to the results aforementioned. When viewing 
results, diazepam is an internal standard with a distinct peak that will show up in the mass 
spectrum. Since equivalent amounts of diazepam and the complex being tested are added, the 
proportion of the peaks that result should be the same between the incubated and the non-
incubated analytes.  
Once the complex travels through the blood, it must be taken up by the cells. It is 
indicated that cisplatin is taken up by cells mostly by passive diffusion.5 Huang et. al sought the 
mechanism by which the complex is taken up by the cell by incubating it in the presence of cell 
uptake inhibitors. Eight different inhibitors of energy dependent and energy independent 
entrance pathways were tested. By using Inductively Coupled Plasma-Mass Spectroscopy (ICP-
MS) the group found that [Ru(bpy)(phpy)(dppz)]+ is not hindered by any uptake inhibitors that 
block energy dependent pathways. Meaning it is most likely taken up by passive diffusion. 
[Ru(bpy)(phpy)(dppz)]+ is only hindered by a high K+ concentration around the cytoplasm. This 
high K+ concentration increases the membrane potential from around -70 to 0mV. Researchers 
hypothesize that the positive charge on the complex makes it susceptible to changes in the cell 
membrane potential.2  
The localization of the drug in cells aids in creating the comprehensive dataset necessary 
to begin formulating the mechanism of the therapeutic in question. Huang, et. al used ICP-MS 
(Inductively coupled plasma mass spectrometry) to test the amount of different ruthenium 
complexes that are able to reach the nucleus following incubation. ICP detects minute 
concentrations as small as one part per 1015, the MS portion allows for quantification. The 
machine nebulizes the analyte and moves it through plasma at a temperature high enough to 
completely atomize the sample. This allows all the atoms present to be quantified individually. In 
the case of precious metal cancer drugs, the metal center is the focus of this method. These 
metals have a high mass relative to the other atoms present in the complex. Due to this element, 
the issue of resolution in the spectra is diminished.  
To test the difference of uptake into the nucleus versus the cytoplasm, a “nuclear and 
cytoplasmic protein extraction kit.” This method requires that technicians start with a known 
concentration of cells and counted following incubation in trypsin—EDTA solution. Next, 
consecutive applications of centrifugation, collection of pellets, and resuspension in the various 
solutions indicated by the kit are needed to separate the cytoplasmic and nuclear fractions 
respectively. Once separated each fraction is tested in the ICP-MS separately and recorded. 
Huang et. al indicated that 90% of the focal ruthenium complex was taken up to the nuclear 
proteins after two hours (Figure 1).2  
 
Figure 1. A representation of the change of concentration in the cytoplasm and the nucleus of 
the three ruthenium complexes tested by Huang et. al over time. 2 
 
Although accumulation in the nucleus is important for an anti-cancer drug, it does not 
necessarily mean the drug will be cytotoxic. Huang, et. al tested cytotoxicity by 2D cancer cell 
culture and 3D multicellular tumor spheroids (MCTSs). 2D analysis requires that a known 
number of cells are cultured on a 96-well flat-bottomed multiwell plate. Huang et. al used 8 
tumor cell lines and one human cell line. Since Cisplatin is the current drug widely used, it was 
also used as an independent variable for the 2D analysis along with [Ru(bpy)2(dppz)]
+ and 
[Ru(bpy)(phpy)(dppz)]+.2 2D analysis is commonly used because many tests can be run can be 
run at a time and results are reached quickly with high reproducibility.3 Incubation for this study 
was 48 hours. For all eight cases of tumor cell lines tested, [Ru(bpy)(phpy)(dppz)]+ is more 
cytotoxic than Cisplatin (Figure 2-2D). An interesting find by this group shows that 
[Ru(bpy)(phpy)(dppz)]+ is even cytotoxic to a Cisplatin resistant line, A549/CDDP. Also, 
[Ru(bpy)(phpy)(dppz)]+ is less cytotoxic to normal human cells. Cytotoxicity was represented as 
IC50 in µM, which is 50 percent of the concentration needed to inhibit cell growth. In the case of 
tumor cells, a lower number is desirable because this means the drug poignantly affects the 
growth mechanism. For healthy cells, the ultimate goal is for a drug that will show as high of a 
concentration as possible. Ultimately, a large disparity between the IC50 of diseased tissue versus 
normal tissue indicates that it is unlikely that the drug will affect both. IC50 for 
[Ru(bpy)(phpy)(dppz)]+ on healthy tissue is shown as 11.5µM, while the number is less than 
4.3µM. This means that [Ru(bpy)(phpy)(dppz)]+ could be more selective than Cisplatin if used in 
cancer therapy.2 While IC50 is the number used to represent the cytotoxicity of a therapeutic, it 
has nothing to do with the actual dosage that would be used when a drug is utilized in a clinical 
setting. The dosage is determined during the first stage of clinical trials. Cytotoxicity 
measurements simply are one of the steps taken in vitro to determine whether or not further 
testing of a drug should be pursued. 
  
 
Figure 2. ‘2D’ shows IC50 values for [Ru(bpy)(phpy)(dppz)]+, Cisplatin, and [Ru(bpy)2(dppz)]+ 
when incubated using 2D cytotoxic analysis. The focus is the comparison of the blue and the red 
especially for culture A and E. A is normal cells while E is a Cisplatin resistant tumor cell type. 
(2D) 
The rest from B-I are other cancerous tissue types. ‘a’ gives IC50 values for the 3 complexes 
aforementioned by comparing the effects on a monolayer versus three sizes of MCTSs.2  
 
The viability of 2D analysis is questioned because there is often a notable deviance 
between in vitro and in vivo results for cytotoxicity.3,14 De Witt Hamer et. al tested how the 
genomes of 2D cell lines and 3D MCTSs changed over a period of two weeks. In the majority of 
the cases, 2D cultures showed low correlation after a two-week period. The samples that did not 
show deviation after two weeks were tested at six and twelve weeks to find if changes may occur 
at those points. Two of the cases in which a high correlation was maintained after two weeks 
were further tested. Results showed that the genome of the primary cell cultures deviate further 
from the parent tumor than the spheroid cultures when tested at 6 and 12 weeks. MCTSs show a 
higher correlation to the parental tumor genome than primary cell cultures after twelve weeks. 
The genetic change is significant, but the study does not claim that this variance is the reason that 
differing results in a lab setting versus testing on small animals. There is simply evidence that the 
biology of 2D cultures are less representative of the tumors. Correlation data is tested by using a 
“genome-wide array comparative genomic hybridization (array CGH). 3  
Huang, et. al included testing of MCTSs to give further information on the cytotoxicity of 
their complexes (Figure 2-a). As previously mentioned, the genomic character of these spheroids 
maintains a better correlation. Other aspects of these cultures that may also contribute to a higher 
reflection of a true tumor are cellular heterogeneity, nutrient and oxygen gradients, and 
proximity interactions of cell matrices. Creating MCTSs requires culturing a cell type followed 
by dissociation into a single cancer cell isolate with a trypsin/EDTA solution. Once isolated the 
cell is cultured to form the spheroid. Huang et. al grew their spheroids to 200, 300, and 400 µm 
and found the cytotoxicity of [Ru(bpy)(phpy)(dppz)]+ as compared to Cisplatin. As the size of 
the MCTSs increased, the cytotoxity decreased. In each case Ru(bpy)(phpy)(dppz)]+ is more 
cytotoxic when compared to Cisplatin. The ruthenium complex shows IC50 values that are 
roughly twenty times lower at each spheroid size.2 The development of 3D cytotoxic analysis 
indicates the importance of researchers continuing to explore better methods of testing. As more 
drugs fail to reach clinical use, researchers must take a step back and evaluate whether or not the 
protocol of getting them there is viable. From the research done on MCTSs, an image of how this 
is done is gained. The more realistic in vitro testing can be; the more confidence scientists can 
have that the therapeutics they create will work. 
One of the ways anticancer drugs can lead to apoptosis is by blocking transcription. To 
do this, the drug must first be taken up the diseased tissue into the nucleus and bind to DNA. 
Once bound to DNA, the complex can block RNA polymerase and/or transcription factors from 
binding. Compound [Ru(bpy)(phpy)(dppz)]+ showed the ability to block transcription and 
specifically a transcription factor called, NF-κB. The in vitro uptake of [Ru(bpy)(phpy)(dppz)]+ 
into the nucleus is 90% after 2 hours of incubation making it an ideal compound to reduce the 
formation of RNA and ultimately proteins through translation once bound. This is the 
mechanism proposed by Huang et. al by which anticancer action occurs.2 Based on these positive 
results, it is likely that researchers will continue to study the molecule discussed by Huang et. al. 
Another way researchers begin to create an understanding of the mechanism is through 
computational chemistry. Vargiu et. al used the computation method of Density Functional 
Theory (DFT) to compute the energy levels of the hydrolysis products of NAMI-A to begin the 
process of understanding its mechanism of action.12 DFT is a method that is commonly applied 
to syntheses. This group compared the energies of the complex when the metal in the plus three 
and plus two oxidation states. As previously noted, ruthenium compounds are stable biologically 
in both oxidation states and the difference in the oxidation can be beneficial for uptake into 
cells.7 Vargiu et. al found that reduction was favored under biological conditions and even more 
so in tumors due to the hypoxic environment of diseased tissue.12,15 Also, the group found that 
hydrolysis of DMSO competes when ruthenium is in the plus three state. While no conclusions 
on how the hydrolysis affects the mechanism were made, the understanding of what hydrolysis 
products are formed helps to move research toward specified study.12 Researchers could use this 
information  Unfortunately, more recent literature explains the compound was not successful in 
phase 2 of clinical trials.6 Therefore, the study to deduce the overall mechanism will not be 
continued unless NAMI-A makes an unforeseen resurgence. 
 
Scheme 1. A display of the structures discussed in “Ruthenium Complexes: Targeting DNA” 
section. 
 
Photodynamic Therapy: Targeting the Mitochondria 
A completely new angle has been sought since finding a ruthenium drug with an 
analogous mechanism to Cisplatin has yet to be created. Photodynamic therapy (PDT) is a 
method that requires a photosensitizer (PS) to be energized by light. Without light radiation, a 
good photosensitizer will be inert in the body. The energy transfers to molecular oxygen species 
that yields reactive oxygen species (ROS).11,14,16 The ROS cause oxidative stress leading to tissue 
[Ru(bpy)(phpy)(dppz)]+ 
NAMI-A 
damage8 to the immediate area in which the photosensitizers accumulate. Being that the 
mitochondria is the powerhouse of the cell, it is an ideal location for the photosensitizers to 
accumulate. Mitochondrion are the primary target because death that starts in these organelles 
tend to lead to apoptosis rather than necrosis of the cell.14 Also, mitochondria targeting 
ruthenium complexes have shown promising cytotoxic effects on Cisplatin resistant tumor 
types9, making PDT agents a desirable replacement for Cisplatin if drugs can be applied 
clinically. 
Many PDT agents yield positive results when tested in vitro, but in vivo results are not as 
promising. The need for a more realistic in vitro test of cytotoxicity to bridge the results2,3 leads 
researchers of PDT agents to focus conclusions of cytotoxicity with the results gathered when 
testing with multicellular spheroids (MCSs). Liu et. al explain that a MCS larger than 200µM  
has a structure able to mimic the environment of tumor better than traditional monolayer 
cultures.14 This is justifiable because the larger the spheroid, the more likely it will be for its 
heterogeneity to be increased.  
Another issue these compounds face is being irradiated once entering the tumor cells 
coupled with the often hypoxic environment of tumors.14,15 The wavelengths of light used for 
radiation can only penetrate so deep when it comes into contact with tissues. Generally, PS are 
excited by light in the UV to the near infrared (NIR). NIR light is able to penetrate deeper than 
light in the UV-Visible range but is still limited. Using UV light can also be damaging to the 
cells by itself. Think about it. Skin cancer can occur from too much exposure to the UV rays of 
the sun. Therefore, it is best to stay away from this type of light since side effects are bound to 
arise.  
There are two methods of irradiation within PDT that are used to excite the compounds. 
Both involve a method called ‘one-photon activation’ uses light from UV-Visible range to excite 
compounds most effectively. When the one-photon method uses light from the NIR, there is not 
enough energy to activate complexes and create ROS. Fortunately, a method that irradiates 
complexes with two photons simultaneously is effective in the NIR. The majority of original PS 
were made within one-photon activation in mind. 17 Because of the desirable penetration of the 
two-photon method, drugs that are receptive to this form of irradiation are highly sought 
after.11,17   
A paper by Liu et. al investigates four ruthenium complexes (Scheme 2) with 4,7-
diphenyl-1,10-phenanthroline (DIP) with the third ligand varying slightly for each. The third 
ligand for RuL1 and RuL2 are available commercially. The difference between L1 and L2 in the 
addition of an arene ring in place of the hydrogen. The L3 and L4 that were used could not be 
acquired commercially and the group synthesized them prior to forming the complexes. L3 
required a four-step synthesis and L4 needs three reactions to be complete. The yield of L3 with 
the methods describe yielded 75% of the theoretical while L4 was 56%. Both are light yellow 
precipitates when formed and purified.14 The ligands for L3 and L4 were created because RuL2 
yields better PDT results than RuL1. The addition of triphenylphosphine (TPP) is added directly 
to the non-DIP ligand in L2 to form L3 and indirectly via a flexible alkyl oxide chain attached to 
L2 with an ether bond. The TPP addition is added to increase the solubility of the complexes and 
in an attempt to add higher selectivity for mitochondria.14 In some cases, increasing the solubility 
negatively affects the cellular uptake of a therapeutic,18 but this is not the case for the TPP 
ligands 3 and 4 used in the study by Liu et. al.14 The researchers noted that ES-MS, IR, 1HNMR, 
and 31PNMR are the methods used to characterize the complexes. This paper describes the 
experiments needed to test PDT agents in vitro. The group sought the two-photon absorption 
(TPA) cross-section, the localization of the substances in cells, and made a comparison of ROS 
production via the one-photon and two-photon methods 
 To find the wavelength at which excitation occurs, the TPA cross section (σ2), 
spectroscopy is used. Equation 1 is dictated as the method for calculating the σ2 at different 
wavelengths. ‘C’ is the concentration in M, ‘I’ is the integrated photoluminescent spectrum, and 
‘n’ is the refractive index. The subscripts ‘S’ and ‘R’ represent whether the variable is sample or 
reference respectively. Rhodimine B is the reference that Liu et. al used for their calculations.14 
The method by which reference values for Rhodimine B are calculated is reported by Xu et. al.19 
Zeng et. al follow a similar methodology in their study. The calculations by Zeng et. al are 
performed at intervals of 10nm in the 2-photon range (760-900 nm14,17) and represented in 
graphical for in Figure 3 with σ2 value on the y-axis and wavelength on the x-axis. A higher 
value is desirable because it indicates that less radiation is needed to excite the drug. The highest 
values for RuL1-L4 occur within the wavelengths 810-830.14 It is reasonable to find such 
similarity for these four complexes due to the high degree of similarity in their ligands. Liu et. al 
report the σ2 values in GM (1 GM = 1 x 10-50 cm s4 photon-1 molecule-1). For the complexes 
tested, the GM values are 124-198, which is much higher than bioactive molecular probes, such 
as; H2TPP. This higher number is inversely proportional to the intensity of the light needed to 
cause excitation of the material. Therefore, the higher the σ2 is the lower the intensity of the light 
used to irradiate the material needs to be. For RuL1-L4, L4 shows the highest GM value of 198 
at 830nm.14 Performing this tests allows researchers to know what wavelengths to use once 
testing of a PS on tumor cells commences. Also, it gives them an idea of which complexes 
should need less light radiation to be activated. 
Equation 1: 𝜎𝑆 = 𝜎𝑅
𝜙𝑅𝐶𝑅𝐼𝑆𝑛𝑆
𝜙𝑆𝐶𝑆𝐼𝑅𝑛𝑅
 
 
Figure 3. A graph showing the TPA cross-sections for the four ruthenium complexes tested by 
Liu et. al at 10 nm intervals. 
 
 Liu et. al used an analogous method to Huang et. al to characterize the uptake location of 
the ruthenium complexes into the cytoplasm and the nucleus. As previously stated, ICP-MS is 
the analytical machine that is able to quantify the small concentrations and their distribution. In 
this case the drug should accumulate in the cytoplasm, since that is the location of the 
mitochondrion. RuL1-RuL4 all accumulate at concentrations above 90% of the incubated 
amount into the cytoplasmic proteins after two hours.  
The step that determines whether or not the drug is targeting the mitochondrion 
specifically distinguishes the experimentation from other types of tracking methods. The 
mitochondrion can be stained and viewed with one- and two-photon luminescent imaging with a 
Laser Scanning Confocal microscope when incubated with MitoTracker Green (MTG). As the 
name suggests, the mitochondrion show up as a bright green color on the image. The Ruthenium 
complexes show up in a bright red color with the same imaging when excited by 458nm light. 
These two images are then compared, and a correlation can be made. RuL4 shows a correlation 
of 0.88 to the MTG image. This correlation factor then is multiplied by the percent concentration 
of the ICP-MS results to yield how much of the substance localizes in the target location. ‘RuL3, 
RuL2, RuL1, RuL4’ is the list of the results in increasing order for percent uptake into the 
mitochondria given by Liu et. al when preforming this method. It is interesting to note that the 
addition of TPP directly gave a less preferential accumulation to the mitochondria. It can be 
concluded that the addition of the TPP does target mitochondrion more preferential when the 
alkyl group spaces it from the non-DIP ligand.14 
 
Figure 4. Images showing the Confocal Laser Microscope images of RuL4 and how the images 
are merged to create the correlation of the complex localization in the mitochondria. 
 
 Since the creation of ROS is key to PDT agents inducing apoptosis, testing for the 
formation of ROS is an important piece of research. This involves incubating the therapeutic in 
question with a molecule like 2,7-dichlorodihydro-fluorescein diacetate (DCFH-DA) that is 
hydrolyzed by esterase enzymes to DCFH. DCFH fluoresces when it comes in contact with 
singlet oxygen (a ROS). This can be imaged with a confocal microscope with the intensity of 
fluorescence directly correlating to the amount of singlet oxygen being formed. Each of the 
compounds show significant fluorescence when irradiated by two-photon light.14 Therefore, ROS 
are being created when the complexes are irradiated. 
 While ROS formation gives confidence that cell death will occur, cytotoxicity tests 
remain an iteration in the research formula. Specifically, cytotoxicity in the dark must be 
measured to ensure the complexes maintain the desired inert capability until irradiated. This 
method is 2D and 3D analysis just as described by Huang et. al.2 In 2D monolayer analysis, IC50 
values for RuL1-L4 have no cytotoxic effects in the dark with concentrations upwards of 100 
µM. Once irradiated with J/cm2, RuL1-RuL3 show IC50 values near twelve, but RuL4 
demonstrations highly positive results as it yields an IC50 of 3.5 µM. This result is expected since 
RuL4 has the highest accumulation in the mitochondrion and high (σ22) value.14 Since RuL4 
gave such positive results in the area of cytotoxicity and has such a large TPA cross section, the 
group performed extra tests to see if the complex would remain cytotoxic when the amount of 
radiation was diminished. This testing was performed using 2D analysis. For the main testing of 
cytotoxicity, the light energy was 12 J/cm2. When the light dosage is diminished to 2 J/cm2 with 
a concentration of 10µM, RuL4 kills 60% of cells after 2 hours. 50% are killed under the same 
conditions when the light is reduced to 1.7 J/cm2. These results point to the positive effects of a 
high TPA cross section coupled with high localization in the mitochondria.14 While 3D analysis 
is considered the best indicator of cytotoxicity, 2D analysis remains an important step for PDT 
cancer research.14,20  
 In regard to 3D analysis, the MCTSs are important since few monolayers can be tested 
with two-photon emission. As previously mentioned, the larger the diameter of the MCTS, the 
better,14 and the increase theoretically gives a closer representation of a tumor in a clinical 
setting. Also, spheroids above 600 µm can produce secondary necroses.20 This is important 
because it will give information as to which type of cell death a complex with induce. If necrosis 
is caused by the cytotoxicity of a therapeutic in vitro, then researchers can critically consider 
whether or not it is worth moving the drug on in testing. With this in mind, Liu et. al report using 
an 800 µm spheroid14, doubling the size mentioned by Huang et. al.2 Testing of uptake into the 
spheroid takes place in an analogous manner to the uptake into the cells of a monolayer. In the 
case of MCTSs, the proposed drug is incubated for 8 hours and then viewed with fluorescence 
microscopy. Each section of depth is recorded to show luminescence. Also, the creation of 
singlet oxygen in the MCTSs is more prevalent near the outside of the culture.14 This is 
explained by the tendency of tumors and spheroids to have a hypoxic core.14,15 RuL4 shows the 
best luminescence for the ROS creation experiment. Finally, the cytotoxicity of RuL4 in the 3D 
analysis is lowest for two-photon absorption at 1.9 µM compared to 9.6 µM for the one-photon 
method.14 All in all, each of the four compounds14 show positive results following these in vitro 
methods. The next step is to perform in vivo testing in hopes that the results continue and lead 
these types of drugs into clincal testing. This paper does not include information on in vivo 
methodology or data. 
 
Scheme 2. Compounds reported by Liu et. al.14 
 
Zeng et. al  used four polypyridyl compounds (Scheme 3) with octupolar organization 
with high chemical and photo stability.9 These compounds are quite similar to those used by Liu 
et. al in that they are polypyridyl compounds. Polypyridyls are able to stabilize electrons in the 
excited state which is the why they are often used in PDT. Zeng’s compounds main difference is 
that they begin to include fluorine substituents that increase lipophilicity. This group focused on 
seeing the uptake of their complexes into different types of cancers cells rather than the normal 
HeLa cells used for this portion of testing by most other groups.2,14 There is not a substantial 
difference for the uptake of the 4 ruthenium complexes into the 3 cacncerous tissues. The 
important things to note from this study about uptake is that Zeng 4 gave the most positive 
results. This compound is the most lipophilic, which indicates that lipophilicity and the uptake 
are directly correlated.9 No indication of the reason for the correlation is given. Next, the group 
also tested uptake into normal cells. For all four ruthenium compounds, the uptake into normal 
cells is noticeably less. This shows some type of preference for tumor cells is can be concluded. 
Since these compounds are PDT agents, it does not seem that this should be as important. It 
seems that this is included because in clinical settings it may be difficult to focus light only onto 
a tumor. There is usually healthy cell surrounding a tumor. If there is not compound in a healthy 
cell, then the possibility of any negative effect to healthy tissue is diminished. Finally, the uptake 
of cisplatin was compared. This was compared because a cisplatin resistance strain was used for 
the research. This is important because the results show that the ruthenium complexes are able to 
localize in a tumor type that cisplatin’s uptake is seriously diminished for. This results shows that 
these complexes could be replacements for cisplatin resistant cancers. 
 Zeng et. al also focuses on the Thioredoxin system as a target for its compounds. This 
system is studied because it includes thioredoxin reductase (TrxR) which activates Trx. Trx 
seeks ROS helping to keep them from causing apoptosis. Also, Trx is involved in protein-protein 
interactions that regulate multiple cellular functions. Multiple cancers upregulate TrxR which 
makes it a possible drug target.9,21 Also, its function in reducing ROS allows it to play a role in 
the resistance of Cisplatin. The tumor lines that are resistant commonly have a high TrxR amount 
or upregulate the production of the compound. When the upregulation of TrxR occurs, the 
resistance is considered “acquired” resistance.21 Zeng et. al tested the effect of their most 
promising probe on TrxR expression. The results show that Zeng’s fourth complex (Zeng 4) 
reduces the expression of TrxR and its activity by 45% which leads to the increase of ROS. 
Ultimately, this causes cell death. The ROS production is monitored with a confocal microscope, 
once again, after incubation with DCFH-DA.9,14 This means the inhibition of TrxR plays a role 
in Zeng 4’s anti-cancer mechansim. 
 Scheme 3. Ruthenium complexes discussed by Zeng et. al.9 
Conclusion: 
Overall, I found it difficult to find multiple further articles on the ruthenium complexes 
{[Ru(bpy)(phpy)(dppz)]+}2 and PDT agent RuL4.14 I believe these two complexes show the 
capability for further investigation of research. Furthering research will create clarity in the 
conclusions and will provide more information about mechanisms of action.  Many of these 
articles indicate the importance of in vivo testing and the difficulties and variance that often arise 
when moving to that step. Therefore, seeing the iterations for the complexes is imperative to the 
process of instating new drugs into chemotherapy. Also, I would like to have seen in vivo based 
articles solely for the purpose of gathering a better understanding into how those types of 
experiments are formatted. It would be beneficial to compare how tumors are cultured and how 
the small animals receive/integrate the tumors. Also, I wonder if cytotoxicity is measured and if 
it is how this is performed. I assume that the process would be highly analogous. 
 I was encouraged on the one hand to see the multitude of ligands that are being studied 
and have literature that can be assessed. It is interesting to see how varying structures do give 
very different functions. I wish there was more information that explained the functionality of 
the ligands rather than simply broad description. Most of the papers simply talk about the results 
the new ligands have and how solubility/lipophilicity are the main factor that change the action 
of the compounds.22 This reasoning was shallow to me because was not developed more by the 
authors. I think this issue would diminish if the drugs showed more success and more research 
focused on a specific drug continued. All the different structures show the lack of success that is 
being had in this area of study. The in vitro results are easier to come by due to more 
reproducibility. The way that spheroids are cultured does lead to some variance, but those 
differences are exacerbated once testing moves on to live testing. Different DNA reacts to drugs 
differently. It is similar to allergies. One person is able to eat gluten without issue while others 
have extreme struggles with the protein. The further into the process of testing the drugs, the 
more factors must be taken into account. I suppose if one takes the Thomas Edison approach, 
then contentment can be maintained. All the failure in research brings scientists one step closer 
to finding more beneficial ways to address cancer.  
 In the end, PDT agents do a good job of taking a novel approach to the problem. But, the 
practicality of radiation to activate hinders the ability to use PDT for cancers in deep tissues. The 
movement toward two-photo excitation aids in this process, but I do not know that PDT alone 
with give a cure-all. It seems that cancer arises in too many forms to simply have one method 
that will negate this type of disease. Also, I thought the focus on the Trx system and its part in 
drug resistance is the kind of information that needs to be continually uncovered for better 
therapeutic designs. The more we understand about how the ligands play vital roles in the 
process of cancer treatment; the easier it will be to tune complexes with the correct ligands.  
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